Abstract
Rationale
Accumulating evidence indicates that the mixed serotonin and dopamine receptor agonist lysergic acid diethylamide (LSD) induces an altered state of consciousness that resembles dreaming.
Objectives
This study aimed to test the hypotheses that LSD produces dreamlike waking imagery and that this imagery depends on 5-HT2A receptor activation and is related to subjective drug effects.
Methods
Twenty-five healthy subjects performed an audiorecorded guided mental imagery task 7 h after drug administration during three drug conditions: placebo, LSD (100 mcg orally) and LSD together with the 5-HT2A receptor antagonist ketanserin (40 mg orally). Cognitive bizarreness of guided mental imagery reports was quantified as a standardised formal measure of dream mentation. State of consciousness was evaluated using the Altered State of Consciousness (5D-ASC) questionnaire.
Results
LSD, compared with placebo, significantly increased cognitive bizarreness (p < 0.001). The LSD-induced increase in cognitive bizarreness was positively correlated with the LSD-induced loss of self-boundaries and cognitive control (p < 0.05). Both LSD-induced increases in cognitive bizarreness and changes in state of consciousness were fully blocked by ketanserin.
Conclusions
LSD produced mental imagery similar to dreaming, primarily via activation of the 5-HT2A receptor and in relation to loss of self-boundaries and cognitive control. Future psychopharmacological studies should assess the differential contribution of the D2/D1 and 5-HT1A receptors to cognitive bizarreness.
Similar content being viewed by others
Notes
As this meditative state progresses, subjects experience a “quasi-reality” with its concomitant feelings and associated affects, which was termed “catathymic imagery” by Leuner (1969).
References
Abramson HA, Jarvik ME, Kaufman MR, Kornetsky C, Levine A, Wagner M (1955) Lysergic acid diethylamide (LSD-25): I. Physiological and perceptual responses. The Journal of Psychology 39(1):3–60. doi:10.1080/00223980.1955.9916156
Achermann P, Rusterholz T, Dürr R, König T, Tarokh L (2016) Global field synchronization reveals rapid eye movement sleep as most synchronized brain state in the human EEG. Royal Society Open Science 3(10):160201. doi:10.1098/rsos.160201
Amargós-Bosch M, Bortolozzi A, Puig MV, Serrats J, Adell A, Celada P, Mengod G, Artigas F, Toth M (2004) Co-expression and in vivo interaction of serotonin 1A and serotonin 2A receptors in pyramidal neurons of prefrontal cortex. Cereb Cortex 14(3):281–299. doi:10.1093/cercor/bhg128
Araneda R, Andrade R (1991) 5-Hydroxytryptamine 2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40(2):399–412. doi:10.1016/0306-4522(91)90128-B
de Araujo DB, Ribeiro S, Cecchi GA, Carvalho FM, Sanchez TA, Pinto JP, de Martinis BS, Crippa JA, Hallak JEC, Santos AC (2012) Seeing with the eyes shut: neural basis of enhanced imagery following ayahuasca ingestion. Hum Brain Mapp 33(11):2550–2560. doi:10.1002/hbm.21381
Baggott MJ (2015) Psychedelics and creativity: a review of the quantitative literature. PeerJ PrePrints 3:e1202v1. doi:10.7287/peerj.preprints.1202v1
Baggott MJ, Siegrist JD, Galloway GP, Robertson LC, Coyle JR, Mendelson JE (2010) Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans. PLoS One 5(12):e14074. doi:10.1371/journal.pone.0014074
Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, Fox SH (2010) Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 67(4):416–421. doi:10.1001/archneurol.2010.35
Braun A (1997) Regional cerebral blood flow throughout the sleep-wake cycle. An H2(15)O PET study. Brain 120(7):1173–1197. doi:10.1093/brain/120.7.1173
Bressloff PC, Cowan JD, Golubitsky M, Thomas PJ, Wiener MC (2002) What geometric visual hallucinations tell us about the visual cortex. Neural Comput 14(3):473–491. doi:10.1162/089976602317250861
Busch AK, Johnson WC (1950) LSD 25 as an aid in psychotherapy; preliminary report of a new drug. Diseases of the nervous system 11(8):241–243
Carhart-Harris R, Nutt D (2014) Was it a vision or a waking dream? Front Psychol 5:255. doi:10.3389/fpsyg.2014.00255
Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, Tagliazucchi E, Schenberg EE, Nest T, Orban C, Leech R, Williams LT, Williams TM, Bolstridge M, Sessa B, McGonigle J, Sereno MI, Nichols D, Hellyer PJ, Hobden P, Evans J, Singh KD, Wise RG, Curran HV, Feilding A, Nutt DJ (2016) Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A 113(17):4853–4858. doi:10.1073/pnas.1518377113
Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX (2005) Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci 17(10):1497–1508. doi:10.1162/089892905774597191
Celada P, Puig MV, Amargós-Bosch M, Adell A, Artigas F (2004) The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 29(4):252–265
Chandler AL, Hartman MA (1960) Lysergic acid diethylamide (LSD-25) as a facilitating agent in psychotherapy. Arch Gen Psychiatry 2(3):286–299. doi:10.1001/archpsyc.1960.03590090042008
Dammann G, Dürsteler-Macfarland KM, Strasser H, Skipper GE, Wiesbeck GA, Wurst FM (2014) Cannabis use among a sample of 16 to 18 year old students in Switzerland. Psychiatr Danub 26(1):56–65
Dittrich A (1996) Aetiologie-unabhängige Strukturen veränderter Wachbewusstseinszustände: Ergebnisse empirischer Untersuchungen über Halluzinogene I. Und II. Ordnung, sensorische Deprivation, hypnagoge Zustände, hypnotische Verfahren sowie Reizüberflutung. VWB, Berlin
Dolder PC, Schmid Y, Haschke M, Rentsch KM, Liechti ME (2015) Pharmacokinetics and concentration-effect relationship of oral LSD in humans. Int J Neuropsychopharmacol 19(1):1–7. doi:10.1093/ijnp/pyv072
Driver H, Flanigan M, Bentley A, Mitchell D, Luus H, Shapiro C (1995) The influence of ipsapirone, a 5-HT1A agonist, on sleep patterns of healthy subjects. Psychopharmacology 117(2):186–192. doi:10.1007/BF02245186
Ermentrout G, Cowan J (1979) A mathematical theory of visual hallucination patterns. Biol Cybernetics 34(3):137–150. doi:10.1007/BF00336965
Ettrup A, Cunha-Bang SD, Mcmahon B, Lehel S, Dyssegaard A, Skibsted AW, Jørgensen LM, Hansen M, Baandrup AO, Bache S, Svarer C, Kristensen JL, Gillings N, Madsen J, Knudsen GM (2014) Serotonin 2A receptor agonist binding in the human brain with [11C] Cimbi-36. J Cereb Blood Flow Metab 34(7):1188–1196. doi:10.1038/jcbfm.2014.68
Family N, Vinson D, Vigliocco G, Kaelen M, Bolstridge M, Nutt DJ, Carhart-Harris RL (2016) Semantic activation in LSD: evidence from picture naming. Language, Cognition and Neuroscience 31(10):1320–1327. doi:10.1080/23273798.2016.1217030
Fischer R, Landon GM (1972) On the arousal state-dependent recall of 'subconscious' experience: stateboundness. Br J Psychiatry 120(555):159–172. doi:10.1192/bjp.120.555.159
Fischman LG (1983) Dreams, hallucinogenic drug states, and schizophrenia: a psychological and biological comparison. Schizophr Bull 9(1):73–94. doi:10.1093/schbul/9.1.73
Fosse R, Stickgold R, Hobson JA (2004) Thinking and hallucinating: reciprocal changes in sleep. Psychophysiology 41(2):298–305. doi:10.1111/j.1469-8986.2003.00146.x
Franke GH, Derogatis LR (1995) Die Symptom-Checkliste von Derogatis SCL-90-R; deutsche Version; Manual. Beltz-Test-GmbH, Göttingen
Frecska E, Móré CE, Vargha A, Luna LE (2012) Enhancement of creative expression and entoptic phenomena as after-effects of repeated ayahuasca ceremonies. J Psychoactive Drugs 44(3):191–199. doi:10.1080/02791072.2012.703099
Frederking W (1955) Intoxicant drugs (mescaline and lysergic acid diethylamide) in psychotherapy. J Nerv Ment Dis 121(3):262–266
Giacomelli S, Palmery M, Romanelli L, Cheng C, Silvestrini B (1998) Lysergic acid diethylamide (LSD) is a partial agonist of D2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro. Life Sci 63(3):215–222. doi:10.1016/S0024-3205(98)00262-8
Gillin J, Jernajczyk W, Valladares-Neto D, Golshan S, Lardon M, Stahl S (1994) Inhibition of REM sleep by ipsapirone, a 5HT1A agonist, in normal volunteers. Psychopharmacology 116(4):433–436. doi:10.1007/BF02247474
Glicksohn J (1992) An exploratory study of syncretic experience: eidetics, synaesthesia and absorption. Perception 21(5):637–642. doi:10.1068/p210637
González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior. Neuron 53(3):439–452. doi:10.1016/j.neuron.2007.01.008
Gottesmann C (2006) The dreaming sleep stage: a new neurobiological model of schizophrenia? Neuroscience 140(4):1105–1115. doi:10.1016/j.neuroscience.2006.02.082
Green WJ (1969) LSD and the sleep-dream cycle. Experimental medicine and surgery 27(1–2):138–144
de Gregorio D, Posa L, Ochoa-Sanchez R, Mclaughlin R, Maione S, Comai S, Gobbi G (2016) The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors. Pharmacol Res 113:81–91. doi:10.1016/j.phrs.2016.08.022
Guilford JP (1967) The nature of human intelligence. McGraw-Hill, New York
Halberstadt AL (2015) Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res 277:99–120. doi:10.1016/j.bbr.2014.07.016
Halberstadt A, Geyer M (2010) LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor. Psychopharmacology 208(2):179–189. doi:10.1007/s00213-009-1718-x
Halberstadt AL, Geyer MA (2011) Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 61(3):364–381. doi:10.1016/j.neuropharm.2011.01.017
Halgren E, Walter RD, Cherlow DG, Crandall PH (1978) Mental phenomena evoked by electrical stimulation of the human hippocampal formation and amygdala. Brain 101(1):83–115. doi:10.1093/brain/101.1.83
Hobson JA (2001) The dream drugstore: chemically altered states of consciousness. MIT Press, Cambridge
Hobson JA (2009) REM sleep and dreaming: towards a theory of protoconsciousness. Nature Reviews Neuroscience 10(11):803–813. doi:10.1038/nrn2716
Jacobs B (1978) Dreams and hallucinations: a common neurochemical mechanism mediating their phenomenological similarities. Neurosci Biobehav Rev 2(1):59–69. doi:10.1016/0149-7634(78)90007-6
Johnson MW, Richards W, Griffiths R (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22(6):603–620. doi:10.1177/0269881108093587
Kahn D (2013) Brain basis of self: self-organization and lessons from dreaming. Front Psychol 4(1):408. doi:10.3389/fpsyg.2013.00408
Kometer M, Schmidt A, Jäncke L, Vollenweider FX (2013) Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci 33(25):10544–10551. doi:10.1523/JNEUROSCI.3007-12.2013
Kometer M, Pokorny T, Seifritz E, Vollenweider FX (2015) Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. Psychopharmacology 232(19):3663–3676. doi:10.1007/s00213-015-4026-7
Krebs-Thomson K, Geyer MA (1998) Evidence for a functional interaction between 5-HT1A and 5-HT2 receptors in rats. Psychopharmacology 140(1):69–74. doi:10.1007/s002130050740
LaBerge S, Rheingold H (1991) Exploring the world of lucid dreaming. Ballantine Books, New York
Lakoff G (1993) How metaphor structures dreams. Dreaming 3(2):77–98. doi:10.1037/h0094373
Landon M, Fischer R (1970) On similar linguistic structures in creative performance and psilocybin-induced experience. Confinia psychiatrica 13(2):115–138
Lebedev AV, Lövdén M, Rosenthal G, Feilding A, Nutt DJ, Carhart-Harris RL (2015) Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin. Hum Brain Mapp 36(8):3137–3153. doi:10.1002/hbm.22833
Leuner H (1968) Basic functions involved in the psychotherapeutic effect of psychotomimetics. In: Shlien JM (ed) Research in psychotherapy. American Psychological Association, Washington, pp 466–470
Leuner H (1969) Guided affective imagery (GAI). A method of intensive psychotherapy. Am J Psychother 23(1):4–21
Leuner H (1973) Creativity and modification of consciousness. Confinia psychiatrica 16(3):141–158
Leuner H (1981) Halluzinogene. Hans Huber, Bern
Leysen JE, Niemegeers CJ, van Nueten JM, Laduron PM (1982) [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol 21(2):301–314
Limosani I, D'Agostino A, Manzone ML, Scarone S (2011) Bizarreness in dream reports and waking fantasies of psychotic schizophrenic and manic patients: empirical evidences and theoretical consequences. Psychiatry Res 189(2):195–199. doi:10.1016/j.psychres.2011.02.023
Llinás R, Ribary U (1993) Coherent 40-Hz oscillation characterizes dream state in humans. Proc Natl Acad Sci U S A 90(5):2078–2081. doi:10.1073/pnas.90.5.2078
Maquet P, Péters J, Aerts J, Delfiore G, Degueldre C, Luxen A, Franck G (1996) Functional neuroanatomy of human rapid-eye-movement sleep and dreaming. Nature 383(6596):163–166. doi:10.1038/383163a0
Marona-Lewicka D, Nichols DE (2007) Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action. Pharmacol Biochem Behav 87(4):453–461. doi:10.1016/j.pbb.2007.06.001
Marona-Lewicka D, Thisted RA, Nichols DE (2005) Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology 180(3):427–435. doi:10.1007/s00213-005-2183-9
Martindale C, Fischer R (1977) The effects of psilocybin on primary process content in language. Confinia psychiatrica 20(4):195–202
Massimini M, Ferrarelli F, Murphy M, Huber R, Riedner B, Casarotto S, Tononi G (2010) Cortical reactivity and effective connectivity during REM sleep in humans. Cognitive neuroscience 1(3):176–183. doi:10.1080/17588921003731578
Mégevand P, Groppe DM, Goldfinger MS, Hwang ST, Kingsley PB, Davidesco I, Mehta AD (2014) Seeing scenes: topographic visual hallucinations evoked by direct electrical stimulation of the parahippocampal place area. J Neurosci 34(16):5399–5405. doi:10.1523/JNEUROSCI.5202-13.2014
Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 27(7):1159–1172. doi:10.1016/j.pnpbp.2003.09.010
Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH (2009) Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology 35(4):881–892. doi:10.1038/npp.2009.176
Merz J, Lehrl S, Galster V, Erzigkeit H (1975) MWT-B: ein Intelligenzkurztest. Psychiatrie Neurologie und Medizinische Psychologie 27(7):423–428
Muthukumaraswamy SD, Carhart-Harris RL, Moran RJ, Brookes MJ, Williams TM, Erritzoe D, Sessa B, Papadopoulos A, Bolstridge M, Singh KD, Feilding A, Friston KJ, Nutt DJ (2013) Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci 33(38):15171–15183. doi:10.1523/JNEUROSCI.2063-13.2013
Muzio JN, Roffwarg HP, Kaufman E (1966) Alterations in the nocturnal sleep cycle resulting from LSD. Electroencephalogr Clin Neurophysiol 21(4):313–324. doi:10.1016/0013-4694(66)90037-X
Nichols DE (2004) Hallucinogens. Pharmacol Ther 101(2):131–181. doi:10.1016/j.pharmthera.2003.11.002
Nir Y, Tononi G (2010) Dreaming and the brain: from phenomenology to neurophysiology. Trends Cogn Sci 14(2):88–100. doi:10.1016/j.tics.2009.12.001
Pace-Schott EF (2008) Serotonin and dreaming. In: Monti JM, Pandi-Perumal SR, Jacobs BL, Nutt DJ (eds) Serotonin and sleep: molecular, functional and clinical aspects. Birkhäuser Verlag, Basel, pp 307–324
Pace-Schott EF, Gersh T, Silvestri R, Stickgold R, Salzman C, Hobson JA (2001) SSRI treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects. J Sleep Res 10(2):129–142. doi:10.1046/j.1365-2869.2001.00249.x
Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008) The pharmacology of lysergic acid diethylamide: a review. CNS neuroscience & therapeutics 14(4):295–314. doi:10.1111/j.1755-5949.2008.00059.x
Persson B, Pettersson A, Hedner T (1987) Pharmacokinetics of ketanserin in patients with essential hypertension. Eur J Clin Pharmacol 32(3):259–265. doi:10.1007/BF00607573
Petri G, Expert P, Turkheimer F, Carhart-Harris R, Nutt D, Hellyer PJ, Vaccarino F (2014) Homological scaffolds of brain functional networks. J R Soc Interface 11(101):20140873. doi:10.1098/rsif.2014.0873
Pines M (1976) A psychoanalytic view of sleep. Postgrad Med J 52(603):26–31. doi:10.1136/pgmj.52.603.26
Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX (2016) Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol 26(4):756–766. doi:10.1016/j.euroneuro.2016.01.005
Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, Liechti ME, Seifritz E, Vollenweider FX (2017) The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol 27(3):451–457. doi:10.1016/j.cub.2016.12.030
Quednow BB, Kometer M, Geyer MA, Vollenweider FX (2012) Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology 37(3):630–640. doi:10.1038/npp.2011.228
Rasmussen AR, Parnas J (2015) Anomalies of imagination and disordered self in schizophrenia spectrum disorders. Psychopathology 48(5):317–323. doi:10.1159/000431291
Rechtschaffen A (1978) The single-mindedness and isolation of dreams. Sleep 1(1):97–109. doi:10.1093/sleep/1.1.97
Rittenhouse CD, Stickgold R, Hobson JA (1994) Constraint on the transformation of characters, objects, and settings in dream reports. Conscious Cogn 3(1):100–113. doi:10.1006/ccog.1994.1007
Roseman L, Sereno MI, Leech R, Kaelen M, Orban C, McGonigle J, Feilding A, Nutt DJ, Carhart-Harris RL (2016) LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion. Hum Brain Mapp 37(8):3031–3040. doi:10.1002/hbm.23224
Sandison RA (1954) Psychological aspects of the LSD treatment of the neuroses. J Ment Sci 100(419):508–515. doi:10.1192/bjp.100.419.508
Sandison RA, Whitelaw JD (1957) Further studies in the therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci 103(431):332–343. doi:10.1192/bjp.103.431.332
Sandison RA, Spencer AM, Whitelaw JD (1954) The therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci 100(419):491–507. doi:10.1192/bjp.100.419.491
Sass LA, Byrom G (2015) Self-disturbance and the bizarre: on incomprehensibility in schizophrenic delusions. Psychopathology 48(5):293–300. doi:10.1159/000437210
Savage C (1955) Variations in ego feeling induced by d-lysergic acid diethylamide (LSD-25). Psychoanal Rev 42(1):1–16
Scarone S, Manzone ML, Gambini O, Kantzas I, Limosani I, D'Agostino A, Hobson JA (2008) The dream as a model for psychosis: an experimental approach using bizarreness as a cognitive marker. Schizophr Bull 34(3):515–522. doi:10.1093/schbul/sbm116
Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Müller F, Borgwardt S, Liechti ME (2015) Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry 78(8):544–553. doi:10.1016/j.biopsych.2014.11.015
Schreiber R, Brocco M, Audinot V, Gobert A, Veiga S, Millan MJ (1995) (1-(2,5-Dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT)2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther 273(1):101–112
Sessa B (2008) Is it time to revisit the role of psychedelic drugs in enhancing human creativity? J Psychopharmacol 22(8):821–827. doi:10.1177/0269881108091597
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The mini-International neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl. 20):22–33
Sinke C, Halpern JH, Zedler M, Neufeld J, Emrich HM, Passie T (2012) Genuine and drug-induced synesthesia: a comparison. Conscious Cogn 21(3):1419–1434. doi:10.1016/j.concog.2012.03.009
Sio U, Monaghan P, Ormerod T (2013) Sleep on it, but only if it is difficult: effects of sleep on problem solving. Mem Cogn 41(2):159–166. doi:10.3758/s13421-012-0256-7
Snyder SH, Faillace LA, Weingartner H (1969) A new psychotropic agent. Psychological and physiological effects of 2,5-dimethoxy-4-ethyl amphetamine (DOET) in man. Arch Gen Psychiatry 21(1):95–101. doi:10.1001/archpsyc.1969.01740190097014
Snyder SH, Weingartner H, Faillace LA (1971) DOET (2,5-dimethoxy-4-ethylamphetamine), a new psychotropic drug: effects of varying doses in man. Arch Gen Psychiatry 24(1):50–55. doi:10.1001/archpsyc.1971.01750070052006
Solms M (2000) Dreaming and REM sleep are controlled by different brain mechanisms. The Behavioral and brain sciences 23(6):843–850. doi:10.1017/S0140525X00003988
Spitzer M, Thimm M, Hermle L, Holzmann P, Kovar K-A, Heimann H, Gouzoulis-Mayfrank E, Kischka U, Schneider F (1996) Increased activation of indirect semantic associations under psilocybin. Biol Psychiatry 39(12):1055–1057. doi:10.1016/0006-3223(95)00418-1
Strassman RJ (1995) Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res 73(1):121–124. doi:10.1016/0166-4328(96)00081-2
Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25(11):1434–1452. doi:10.1177/0269881110382466
Stumbrys T, Erlacher D, Malinowski P (2015) Meta-awareness during day and night. Imagination, Cognition and Personality 34(4):415–433. doi:10.1177/0276236615572594
Sweat N, Bates L, Hendricks PS (2016) The associations of naturalistic classic psychedelic use, mystical experience, and creative problem solving. J Psychoactive Drugs 48(5):344–350. doi:10.1080/02791072.2016.1234090
Tagliazucchi E, Carhart-Harris R, Leech R, Nutt D, Chialvo DR (2014) Enhanced repertoire of brain dynamical states during the psychedelic experience. Hum Brain Mapp 35(11):5442–5456. doi:10.1002/hbm.22562
Terhune DB, Luke DP, Kaelen M, Bolstridge M, Feilding A, Nutt D, Carhart-Harris R, Ward J (2016) A placebo-controlled investigation of synaesthesia-like experiences under LSD. Neuropsychologia 88:28–34. doi:10.1016/j.neuropsychologia.2016.04.005
Thompson DF, Pierce DR (1999) Drug-induced nightmares. Ann Pharmacother 33(1):93–98. doi:10.1345/aph.18150
Torda C (1968) Contribution to serotonin theory of dreaming (LSD infusion). New York state journal of medicine 68(9):1135–1138
Valle M, Maqueda AE, Rabella M, Rodríguez-Pujadas A, Antonijoan RM, Romero S, Alonso JF, Mañanas MÀ, Barker S, Friedlander P, Feilding A, Riba J (2016) Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. Eur Neuropsychopharmacol 26(7):1161–1175. doi:10.1016/j.euroneuro.2016.03.012
Vollenweider FX, Geyer MA (2001) A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 56(5):495–507. doi:10.1016/S0361-9230(01)00646-3
Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16(5):357–372. doi:10.1016/S0893-133X(96)00246-1
Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9(17):3897–3902
Voss U, Holzmann R, Hobson A, Paulus W, Koppehele-Gossel J, Klimke A, Nitsche MA (2014) Induction of self awareness in dreams through frontal low current stimulation of gamma activity. Nat Neurosci 17(6):810–812. doi:10.1038/nn.3719
Wagner U, Gais S, Haider H, Verleger R, Born J (2004) Sleep inspires insight. Nature 427(6972):352–355. doi:10.1038/nature02223
Weingartner H, Snyder SH, Faillace LA, Markley H (1970) Altered free associations: some cognitive effects of DOET (2,5-dimethoxy-4-ethylamphetamine). Behav Sci 15(4):297–303. doi:10.1002/bs.3830150402
Weintraub W, Silverstein AB, Klee GD (1959) The effect of LSD on the associative processes. J Nerv Ment Dis 128(5):409–414
Williams J, Merritt J, Rittenhouse C, Hobson JA (1992) Bizarreness in dreams and fantasies. Conscious Cogn 1(2):172–185. doi:10.1016/1053-8100(92)90059-J
Wittchen H-U, Fydrich T (1997) Strukturiertes Klinisches Interview für DSM-IV (SKID-I und SKID-II). Hogrefe, Göttingen
Acknowledgements
This study was financially supported by grants from the Heffter Research Institute (1-190413), the Swiss Neuromatrix Foundation (2015-0103), the Usona Institute (2015-2056) and the Swiss National Science Foundation (SNSF, P2ZHP1_161626).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Rights and permissions
About this article
Cite this article
Kraehenmann, R., Pokorny, D., Vollenweider, L. et al. Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology 234, 2031–2046 (2017). https://doi.org/10.1007/s00213-017-4610-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-017-4610-0